2-(3-amino-4-ethoxyphenyl)-5-phenylbenzoxazole | 599202-38-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-(3-amino-4-ethoxyphenyl)-5-phenylbenzoxazole
• 英文别名: 2-ethoxy-5-(5-phenyl-1,3-benzoxazol-2-yl)aniline
• CAS: 599202-38-7
• 化学式: C₂₁H₁₈N₂O₂
• 分子量: 330.386
• InChiKey: LYPOQHWCNSYNLV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  25
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  61.3
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  偏苯三酸酐 、 2-(3-amino-4-ethoxyphenyl)-5-phenylbenzoxazole 在 溶剂黄146 作用下， 生成 2-[2-ethoxy-5-(5-phenylbenzoxazol-2-yl)phenyl]-1,3-dioxo-2,3-dihydro-1H-isoindole-5-carboxylic acid
  参考文献：
  名称：

  2,3-Dihydro-1,3-dioxo-1H-isoindole-5-carboxylic acid derivatives: a novel class of small molecule heparanase inhibitors

  摘要：

  A novel class of 2,3-dihydro-1,3-dioxo-1H-isoindole-5-carboxylic acids are described as inhibitors of the endo-beta-glucuronidase heparanase. Several of the compounds, for example, 2-[4-propylamino-5-[5-(4-chloro)phenyl-benzoxazol-2-yl]phenyl]-2,3-dihydro-1,3-dioxo-IH-isoindole-5-carboxylic acid (9c), display potent heparanase inhibitory activity (IC50 200-500nM) and have high selectivity ( > 100-fold) over human beta-glucuronidase. They also show anti-angiogenic effects. Such compounds should serve as useful biological tools and may provide a basis for the design of novel therapeutic agents. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.03.086
• 作为产物：
  描述：

  2-(3-nitro-4-ethoxyphenyl)-5-phenylbenzoxazole 在 钯 碳 作用下， 以 1,4-二氧六环 为溶剂， 以gave the crude subtitle compound (51 mg, 56%) as a white solid which的产率得到2-(3-amino-4-ethoxyphenyl)-5-phenylbenzoxazole
  参考文献：
  名称：

  Phthalimide carboxylic acid derivatives

  摘要：

  本发明涉及公式（I）的邻苯二甲酰亚胺羧酸衍生物，其制备方法，包含它们的制药组合物以及它们在医学上的用途，特别是在癌症治疗中。其中，X为O或S；R1是公式（II）的邻苯二甲酰亚胺羧酸基团。R为氢，C1-C6烷基，芳基或C1-C3烷基芳基，而R2，R3和R4代表各种取代基。

  公开号：

  US20050203153A1

文献信息

• [EN] PHTHALIMIDE CARBOXYLIC ACID DERIVATIVES<br/>[FR] DERIVES D'ACIDES CARBOXYLIQUES PHTALIMIDIQUES
  申请人：OXFORD GLYCOSCIENCES UK LTD

  公开号：WO2003074516A1

  公开（公告）日：2003-09-12

  The present invention relates to phthalimide carboxylic acid derivatives of formula (I), methods for their preparation, pharmaceutical compositions containing them and their use in medicine, specifically in the treatment of cancer. (I), wherein X is O or S; R1 is a phthalimide carboxylic acid group of formula (II). R is hydrogen, C1-C6 alkyl, aryl or C1-C3 alkylaryl and R2, R3 and R4 represent various substituents.

  本发明涉及公式（I）的邻苯二甲酰亚胺羧酸衍生物，其制备方法，含有它们的药物组合物以及它们在医学中的应用，具体用于癌症治疗。在公式（I）中，X为O或S；R1为公式（II）的邻苯二甲酰亚胺羧酸基团。R为氢、C1-C6烷基、芳基或C1-C3烷基芳基，R2、R3和R4代表各种取代基。
• Phthalimide carboxylic acid derivatives
  申请人：Courtney Martin Stephen

  公开号：US20050203153A1

  公开（公告）日：2005-09-15

  The present invention relates to phthalimide carboxylic acid derivatives of formula (I), methods for their preparation, pharmaceutical compositions containing them and their use in medicine, specifically in the treatment of cancer. (I), wherein X is O or S; R 1 is a phthalimide carboxylic acid group of formula (II). R is hydrogen, C 1 -C 6 alkyl, aryl or C 1 -C 3 alkylaryl and R 2 , R 3 and R 4 represent various substituents.

  本发明涉及公式（I）的邻苯二甲酰亚胺羧酸衍生物，其制备方法，包含它们的制药组合物以及它们在医学上的用途，特别是在癌症治疗中。其中，X为O或S；R1是公式（II）的邻苯二甲酰亚胺羧酸基团。R为氢，C1-C6烷基，芳基或C1-C3烷基芳基，而R2，R3和R4代表各种取代基。
• PHTHALIMIDE CARBOXYLIC ACID DERIVATIVES
  申请人：Oxford GlycoSciences (UK) Ltd,Attn: Mary Gadsden

  公开号：EP1483261A1

  公开（公告）日：2004-12-08
• US7138425B2
  申请人：——

  公开号：US7138425B2

  公开（公告）日：2006-11-21
• 2,3-Dihydro-1,3-dioxo-1H-isoindole-5-carboxylic acid derivatives: a novel class of small molecule heparanase inhibitors
  作者：Stephen M. Courtney、Philip A. Hay、Richard T. Buck、Claire S. Colville、David W. Porter、David I.C. Scopes、Faye C. Pollard、Martin J. Page、James M. Bennett、Margaret L. Hircock、Edward A. McKenzie、Colin R. Stubberfield、Paul R. Turner

  DOI：10.1016/j.bmcl.2004.03.086

  日期：2004.6

  A novel class of 2,3-dihydro-1,3-dioxo-1H-isoindole-5-carboxylic acids are described as inhibitors of the endo-beta-glucuronidase heparanase. Several of the compounds, for example, 2-[4-propylamino-5-[5-(4-chloro)phenyl-benzoxazol-2-yl]phenyl]-2,3-dihydro-1,3-dioxo-IH-isoindole-5-carboxylic acid (9c), display potent heparanase inhibitory activity (IC50 200-500nM) and have high selectivity ( > 100-fold) over human beta-glucuronidase. They also show anti-angiogenic effects. Such compounds should serve as useful biological tools and may provide a basis for the design of novel therapeutic agents. (C) 2004 Elsevier Ltd. All rights reserved.